Are you above the legal age to view this content in your province/state?

Home / Industry News / A cannabis chemical may have a “major impact” in the treatment of pancreatic cancer

A cannabis chemical may have a “major impact” in the treatment of pancreatic cancer

A cannabis chemical may have a “major impact” in the treatment of pancreatic cancer

U.S., August 21, 2019 (INDEPENDENT)- A cannabis chemical may have a “major impact” in the treatment of pancreatic cancer, according to a new study.

Pancreatic cancer has a five-year survival rate of just nine per cent, according to the American Cancer Society (ACS), and is expected to be the second leading cause of cancer deaths in the United States by 2020.

However, a Harvard University study conducted by researchers at the university’s Dana-Farber Cancer Institute and published in the Frontiers of Oncology has found that FBL-03G – a “non-cannabinoid, non-psychoactive derivative of cannabis” – has “significant therapy potential” in treating the disease.

FBL-03G is a derivative of a cannabis “flavonoid”, naturally occurring compounds found in plants, fruits and vegetables, which are known to have certain health benefits. But this study has found that the flavonoid derivative in question may be able to treat both localised and advanced pancreatic cancer.

“The most significant conclusion is that tumour-targeted delivery of flavonoids, derived from cannabis, enabled both local and metastatic tumour cell kill, significantly increasing survival from pancreatic cancer,” one of the study’s researchers, Dr Wilfred Ngwa, told Yahoo. “This has major significance, given that pancreatic cancer is particularly refractory to current therapies.”

The study suggests that FBL-03G is capable of attacking other cancer cells and stopping their growth. “We were quite surprised that the drug could inhibit the growth of cancer cells in other parts of the body, representing metastasis, that were not targeted by the treatment,” says Dr Ngwa.

Ultimately, this would mean extending the life expectancy of those with pancreatic cancer, which is often diagnosed when it is in a later stage and has already spread.

The study so far has only been tested on small animals but after the positive results researchers have recommended further studies with the ultimate goal of clinical translation.

The next step for researchers is to complete pre-clinical studies, according to Dr Ngwa, who hopes that these will be completed by 2020.

Disclaimer

Investment Value Finders specializes in providing opinions and information on stocks to individuals who wish to receive them. Our reports are construed for information purposes solely and are distributed free of charge to individuals who wish to receive them.


Investment Value Finders does not promote, condone or advocate licit or illicit drug use. Investment Value Finders cannot be held responsible for materials or contests posted on its website pages, or pages to which we provide links, which promote, condone or advocate licit or illicit drug use or illegal activities.


DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS WEBSITE. We are not registered as a securities broker-dealer or an investment adviser. We are neither licensed nor qualified to provide investment advice.


Investment Value Finders occasionally receives direct compensation for hosting links (or other* advertisements) to third party content that may be subject to disclaimer pursuant to Section 17(b) of the Securities Act of 1933. For those instances where the link text contains company or stock-specific mention, we provide the following list of compensation received in order to ensure full disclosure and transparency.


Investment Value Finders is intended for those 21+ years of age only!

Check Also

FSD Pharma Talks About Their Expanding Revenue Potential

FSD Pharma Talks About Their Expanding Revenue Potential

Phoenix, Arizona–(Newsfile Corp. – September 12, 2019) – The Stock Day Podcast welcomed FSD Pharma …